Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Giebel

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Bone Marrow Transplantation|January 8, 2013
Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizersS Giebel, T Kruzel, T Czerw, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registryA Sadowska-Klasa, J M Zaucha, M Labopin, et al.
Bone Marrow Transplantation|July 12, 2005
The immunosuppressive effect of human cytomegalovirus infection in recipients of allogeneic hematopoietic stem cell transplantationS Giebel, R Maccario, D Lilleri, et al.
Journal of Internal Medicine|October 14, 2017
What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?O Ringdén, M Labopin, B Sadeghi, et al.
Bone Marrow Transplantation|October 27, 2009
Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALLS Giebel, B Stella-Holowiecka, M Krawczyk-Kulis, et al.
Bone Marrow Transplantation|July 10, 2012
The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMTS Giebel, M Labopin, M Mohty, et al.
Bone Marrow Transplantation|January 29, 2013
Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centersA Bazarbachi, M Labopin, A Ghavamzadeh, et al.
Bone Marrow Transplantation|June 2, 2015
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMTJ R Passweg, M Labopin, J Cornelissen, et al.
Bone Marrow Transplantation|December 1, 2015
Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMTX Cahu, M Labopin, S Giebel, et al.
Bone Marrow Transplantation|December 14, 2011
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioningJ Casper, J Holowiecki, R Trenschel, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Bone Marrow Transplantation|January 8, 2013
Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizersS Giebel, T Kruzel, T Czerw, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registryA Sadowska-Klasa, J M Zaucha, M Labopin, et al.
Bone Marrow Transplantation|July 12, 2005
The immunosuppressive effect of human cytomegalovirus infection in recipients of allogeneic hematopoietic stem cell transplantationS Giebel, R Maccario, D Lilleri, et al.
Journal of Internal Medicine|October 14, 2017
What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?O Ringdén, M Labopin, B Sadeghi, et al.
Bone Marrow Transplantation|October 27, 2009
Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALLS Giebel, B Stella-Holowiecka, M Krawczyk-Kulis, et al.
Bone Marrow Transplantation|July 10, 2012
The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMTS Giebel, M Labopin, M Mohty, et al.
Bone Marrow Transplantation|January 29, 2013
Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centersA Bazarbachi, M Labopin, A Ghavamzadeh, et al.
Bone Marrow Transplantation|June 2, 2015
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMTJ R Passweg, M Labopin, J Cornelissen, et al.
Bone Marrow Transplantation|December 1, 2015
Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMTX Cahu, M Labopin, S Giebel, et al.
Bone Marrow Transplantation|December 14, 2011
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioningJ Casper, J Holowiecki, R Trenschel, et al.
Pageof 4